Duration of therapy is an important factor determining patients' compliance in dermatomycosis clinical practice. We undertook a prospective, randomised, doubleblind, parallel group study to investigate the ef cacy and tolerability of once daily treatment with terbina ne 1% cream for 1 week, compared to its vehicle, in adult patients with interdigital tinea pedis. Ef cacy was assessed in terms of mycological cure, total clinical signs and symptoms scores, and clinical response, 1 day and 1, 5 and 7 weeks after end of treatment. Terbina ne 1% cream was signi cantly more effective than its vehicle in achieving and maintaining mycological cure for 7 weeks: 91¢4% vs. 37¢1%, P < 0¢001. Terbina ne was also signi cantly more effective than its vehicle in reducing total clinical signs and symptoms scores, and in achieving clinical response. We conclude that terbina ne 1% cream, applied once daily for 7 days, is an effective and well-tolerated treatment for interdigital tinea pedis in nonimmunocompromised patients. The short duration of treatment needed to achieve mycological cure has important implications for patient compliance and for control of infection within the community.